| Literature DB >> 32985509 |
Gopal Nambi1, Walid Kamal Abdelbasset2,3, Shereen H Elsayed4, Mona A Khalil5, Saud M Alrawaili2, Saud F Alsubaie2.
Abstract
The objective of this study is to compare the effects of virtual reality training (VRT) and sensory-motor training (SMT) in bone morphogenetic proteins (BMP) and inflammatory biomarkers expression in post-traumatic osteoarthritis (PTOA) after the anterior cruciate ligament injury. Through a simple random sampling method, 60 eligible participants were allocated into VRT (n = 20), SMT (n = 20), and control groups (n = 20). They underwent training programs for 4 weeks. Clinical (pain intensity and functional disability) and biochemical (bone morphogenic proteins and inflammatory biomarkers) values were measured at baseline, after 4 weeks, 8 weeks and 3 months follow up. Four weeks following training, the VRT group shows more significant changes in pain intensity and functional disability than SMT and control groups (P < 0.001). Bone morphogenic protein (BMP) measures such as BMP 2, 4, 6, and 7 don't show any significant changes between the groups. But at the same time, the VRT group shows positive improvement in inflammatory biomarkers (CRP, TNF-α, IL-2, IL-4, IL-6) analysis than the other two groups (P < 0.001). Our study suggests that including virtual reality training in PTOA shows beneficial changes in pain, functional disability, and modification of inflammatory biomarkers than sensory-motor training, but at the same time it shows a negligible effect on bone morphogenic proteins.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32985509 PMCID: PMC7523000 DOI: 10.1038/s41598-020-72587-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Flow chart showing the study details.
One way ANOVA analysis of demographic details of VRT, SMT and Control group.
| Sr. no | Variable | VRT | SMT | Control | P-value |
|---|---|---|---|---|---|
| 1 | Age (y) | 22.8 ± 1.3 | 22.6 ± 1.4 | 21.9 ± 1.3 | 0.090 |
| 2 | Height (m) | 1.74 ± 0.16 | 1.75 ± 0.15 | 1.73 ± 0.16 | 0.921 |
| 3 | Weight (kg) | 65.5 ± 3.1 | 66.7 ± 2.9 | 67.6 ± 2.8 | 0.085 |
| 4 | BMI (kg/m2) | 22.4 ± 1.6 | 22.5 ± 1.5 | 23.1 ± 1.4 | 0.288 |
| 5 | VO2peak (ml/kg/min) | 37.5 ± 3.6 | 37.3 ± 3.9 | 38.2 ± 4.1 | 0.743 |
| 6 | HR (beats/min) | 168 ± 7.2 | 169 ± 7.1 | 166 ± 7.5 | 0.419 |
| 7 | Years of playing (y) | 4.9 ± 2.1 | 5.2 ± 1.9 | 5.4 ± 1.8 | 0.715 |
| 8 | Duration of pain (m) | 4.8 ± 1.2 | 4.2 ± 1.1 | 5.1 ± 1.3 | 0.630 |
VRT virtual reality training, SMT sensory motor training, SD standard deviation, BMI Body Mass Index, VO oxygen volume, HR heart rate, y years, m months.
Pre and post VAS and WOMAC analysis of VRT, SMT and Control group.
| Sr. no | Variable | VRT | SMT | Control | P-value | |
|---|---|---|---|---|---|---|
| 1 | Pain intensity (VAS) | Base line | 7.2 ± 0.5 | 7.4 ± 0.4 | 7.3 ± 0.4 | 0.355 |
| 4 weeks | 3.3 ± 0.4 | 5.8 ± 0.5 | 6.5 ± 0.5 | 0.001* | ||
| 8 weeks | 2.5 ± 0.4 | 3.5 ± 0.5 | 4.2 ± 0.5 | 0.001* | ||
| 3 months | 0.5 ± 0.3 | 1.5 ± 0.4 | 3.8 ± 0.4 | 0.001* | ||
| P-value | 0.001* | 0.001* | 0.001* | |||
| 2 | Functional disability (WOMAC) | Base line | 72.33 ± 4.2 | 72.47 ± 4.5 | 71.22 ± 3.8 | 0.587 |
| 4 weeks | 34.11 ± 3.4 | 56.32 ± 3.8 | 62.28 ± 3.2 | 0.001* | ||
| 8 weeks | 22.41 ± 2.1 | 32.35 ± 2.8 | 52.28 ± 3.2 | 0.001* | ||
| 3 months | 11.21 ± 2.1 | 25.32 ± 2.1 | 35.22 ± 2.8 | 0.001* | ||
| P-value | 0.001* | 0.001* | 0.001* | |||
*Significant, VRT virtual reality training, SMT sensory motor training, SD standard deviation.
Figure 2Mean values of VAS and WOMAC scores in VRT, SMT and control group.
Pre and post bone morphogenic protein analysis of VRT, SMT and control group.
| Sr. no | Variable | VRT | SMT | Control | P-value | |
|---|---|---|---|---|---|---|
| 1 | BMP-2 (pg/ml) | Base line | 657.12 ± 8.1 | 656.33 ± 8.9 | 656.22 ± 8.5 | 0.935 |
| 4 weeks | 656.45 ± 7.1 | 656.22 ± 7.2 | 655.72 ± 7.1 | 0.946 | ||
| 8 weeks | 656.45 ± 7.2 | 656.01 ± 7.3 | 655.48 ± 9.2 | 0.928 | ||
| 3 months | 655.92 ± 7.5 | 656.23 ± 7.4 | 655.28 ± 9.8 | 0.934 | ||
| P-value | 0.967 | 0.999 | 0.987 | |||
| 2 | BMP-4 (pg/ml) | Base line | 643.21 ± 7.9 | 643.66 ± 7.8 | 642.89 ± 7.6 | 0.951 |
| 4 weeks | 642.88 ± 7.2 | 642.58 ± 7.6 | 642.28 ± 7.4 | 0.967 | ||
| 8 weeks | 642.43 ± 7.3 | 642.45 ± 7.2 | 642.15 ± 7.4 | 0.989 | ||
| 3 months | 642.15 ± 7.6 | 642.11 ± 7.5 | 642.03 ± 7.9 | 0.984 | ||
| P-value | 0.971 | 0.923 | 0.841 | |||
| 3 | BMP-6 (pg/ml) | Base line | 698.88 ± 9.2 | 699.78 ± 9.4 | 698.76 ± 9.5 | 0.931 |
| 4 weeks | 698.57 ± 8.5 | 699.46 ± 8.3 | 698.59 ± 8.5 | 0.930 | ||
| 8 weeks | 698.36 ± 8.2 | 699.35 ± 8.3 | 698.28 ± 8.3 | 0.901 | ||
| 3 months | 698.12 ± 8.1 | 699.12 ± 8.2 | 698.11 ± 8.3 | 0.904 | ||
| P-value | 0.993 | 0.994 | 0.995 | |||
| 4 | BMP-7 (pg/ml) | Base line | 241.32 ± 8.3 | 240.57 ± 8.2 | 241.33 ± 8.3 | 0.946 |
| 4 weeks | 241.22 ± 7.5 | 240.33 ± 6.3 | 240.81 ± 7.5 | 0.924 | ||
| 8 weeks | 240.92 ± 7.3 | 239.97 ± 6.8 | 240.49 ± 7.3 | 0.915 | ||
| 3 months | 240.88 ± 7.4 | 239.68 ± 7.3 | 240.34 ± 7.4 | 0.977 | ||
| P-value | 0.997 | 0.980 | 0.930 | |||
VRT virtual reality training, SMT sensory motor training, BMP bone morphogenic proteins, SD standard deviation.
Figure 3Mean values of BMP-2, BMP-4, BMP-6 and BMP-7 levels in VRT, SMT and control groups.
Pre and post pro inflammatory biomarker analysis of VRT, SMT and Control group.
| Sr. no. | Variable | VRT | SMT | Control | P-value | |
|---|---|---|---|---|---|---|
| 1 | CRP (mg/l) | Pre | 1.55 ± 0.4 | 1.54 ± 0.4 | 1.52 ± 0.4 | 0.971 |
| 4 weeks | 1.08 ± 0.4 | 1.48 ± 0.3 | 1.45 ± 0.2 | 0.001* | ||
| 8 weeks | 0.57 ± 0.2 | 1.23 ± 0.3 | 1.38 ± 0.3 | 0.002* | ||
| 3 months | 0.32 ± 0.2 | 0.98 ± 0.4 | 1.29 ± 0.4 | 0.001* | ||
| P-value | 0.001* | 0.001* | 0.173* | |||
| 2 | TNF-α (Pg/ml) | Pre | 15.92 ± 0.7 | 15.48 ± 0.6 | 15.92 ± 0.8 | 0.832 |
| 4 weeks | 10.47 ± 0.4 | 14.52 ± 0.4 | 15.32 ± 0.4 | 0.001* | ||
| 8 weeks | 8.23 ± 0.5 | 13.21 ± 0.4 | 14.56 ± 0.5 | 0.001* | ||
| 3 months | 7.21 ± 0.3 | 11.89 ± 0.4 | 14.11 ± 0.4 | 0.001* | ||
| P-value | 0.001* | 0.001* | 0.001* | |||
| 3 | IL-2 | Pre | 12.89 ± 1.1 | 12.26 ± 0.9 | 12.92 ± 1.2 | 0.990 |
| 4 weeks | 13.56 ± 0.7 | 12.88 ± 0.7 | 12.98 ± 0.9 | 0.015* | ||
| 8 weeks | 14.98 ± 0.6 | 13.74 ± 0.6 | 13.21 ± 0.7 | 0.001* | ||
| 3 months | 16.02 ± 0.6 | 13.93 ± 0.6 | 13.38 ± 0.5 | 0.001* | ||
| P-value | 0.001* | 0.001* | 0.313 | |||
| 4 | IL-4 | Pre | 39.94 ± 0.7 | 39.43 ± 0.8 | 38.95 ± 0.8 | 0.057 |
| 4 weeks | 48.65 ± 0.8 | 43.61 ± 0.7 | 39.89 ± 0.7 | 0.001* | ||
| 8 weeks | 59.32 ± 0.7 | 52.38 ± 0.8 | 41.32 ± 0.7 | 0.001* | ||
| 3 months | 65.11 ± 0.9 | 56.38 ± 0.9 | 42.28 ± 0.8 | 0.001* | ||
| P-value | 0.001* | 0.001* | 0.075 | |||
| 5 | IL-6 | Pre | 5.8 ± 0.4 | 5.6 ± 0.5 | 5.5 ± 0.4 | 0.094 |
| 4 weeks | 3.5 ± 0.3 | 5.1 ± 0.2 | 5.2 ± 0.2 | 0.001* | ||
| 8 weeks | 2.3 ± 0.2 | 4.8 ± 0.3 | 5.2 ± 0.2 | 0.001* | ||
| 3 months | 1.2 ± 0.1 | 3.8 ± 0.3 | 4.9 ± 0.4 | 0.001* | ||
| P-value | 0.001* | 0.001* | 0.603 | |||
*Significant, VRT virtual reality training, SMT sensory motor training, CRP C reactive protein, TNF tumor necrosis factor, IL interleukin, SD standard deviation.
Figure 4Mean values of CRP, TNF-α, IL-2, IL-4 and IL-6 levels in VRT, SMT and control group.